Skip to content
Approval of respiratory syncytial virus vaccine is a first for people 60 years and older, company says
Source link
Tags: C&E Industry News Filter, Content Types, corporate, Corporate/Industrial News, Demographic Health, development, Factiva Filters, general news, Geriatric Health, government policy, GSK, GSK.LN, Health, healthcare, Healthcare/Life Sciences, Immunizations, industrial news, life sciences, Medical Conditions, medical treatments, Medical Treatments/Procedures, medications, new product, New Product/Service Testing, new products, New Products/Services, Pharmaceuticals, political, Political/General News, procedures, product, Product/Service Approvals, products, Products/Services, regulation, Regulation/Government Policy, research, Research/Development, Respiratory Tract Diseases, service approvals, service testing, services, specialized drugs, Specialized Drugs/Medications, SYND, UK:GSK, Vaccines, WSJ-PRO-WSJ.com
